These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 32243222)

  • 1. Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
    Frosch ZAK; Landsburg DJ
    J Clin Oncol; 2020 Jun; 38(18):2014-2017. PubMed ID: 32243222
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
    Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
    Dunleavy K; Davis RE; Landgren O; Staudt LM; Wilson WH
    Blood; 2007 Jan; 109(2):843-4; discussion 844-5. PubMed ID: 17210865
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
    Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
    J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
    Coiffier B; Salles G
    Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
    [No Abstract]   [Full Text] [Related]  

  • 10. CHOP plus rituximab--balancing facts and opinion.
    Cheson BD
    N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma and Burkitt lymphoma: a report of two cases.
    Zhang S; Wilson D; Czader M
    Ann Lab Med; 2015 Mar; 35(2):254-6. PubMed ID: 25729731
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
    Bewarder M; Kaddu-Mulindwa D; Kos IA; Lesan V; Held G; Poeschel V; Thurner L; Bittenbring JT; Schmitz N; Truemper L; Pfreundschuh M; Christofyllakis K; Loeffler M; Altmann B; Ziepert M
    Haematologica; 2023 Oct; 108(10):2844-2849. PubMed ID: 36815369
    [No Abstract]   [Full Text] [Related]  

  • 13. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
    Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
    Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
    Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
    [No Abstract]   [Full Text] [Related]  

  • 15. [Significance and application of c-myc in diffuse large B-cell lymphoma].
    Huang WT; Lü N; Guo L
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
    [No Abstract]   [Full Text] [Related]  

  • 16. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [B-cell lymphoma with concurrent myc/IgH and bcl-2/IgH translocations: report of a case].
    Li L; Liu YH; Zhuang HG; Luo DL; Xu FP; Luo XL; Xu J; Zhang KP
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):50-1. PubMed ID: 21429362
    [No Abstract]   [Full Text] [Related]  

  • 18. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
    Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
    Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
    Nascimento AF; Winters GL; Pinkus GS
    Am J Surg Pathol; 2007 Sep; 31(9):1344-50. PubMed ID: 17721189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.
    Oncologist; 2020 Jul; 25 Suppl 1(Suppl 1):S14-S15. PubMed ID: 32588924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.